Impilo Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 25-06-2024
- Paid Up Capital ₹ 0.30 M
as on 25-06-2024
- Company Age 9 Year, 11 Months
- Last Filing with ROC 31 Mar 2019
- Revenue 20.36%
(FY 2019)
- Profit 198.18%
(FY 2019)
- Ebitda 79.77%
(FY 2019)
- Net Worth 36.04%
(FY 2019)
- Total Assets 27.83%
(FY 2019)
About Impilo Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 0.30 M, as per Ministry of Corporate Affairs (MCA) records.
Sandhya Shinge, Vijay Eshwarappa, Kannambadi Subramaniam, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24232KA2015PTC078093
- Company No.
078093
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Jan 2015
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Impilo Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kannambadi Subramaniam  | Managing Director | 05-Jan-2015 | Current |
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sandhya Shinge | Additional Director | 02-Aug-2016 | Current |
| Vijay Eshwarappa | Whole-Time Director | 05-Jan-2015 | Current |
| Ravishankar Krishnamurthy | Whole-Time Director | 05-Jan-2015 | Current |
| Pradeep Siddegowda | Whole-Time Director | 05-Jan-2015 | Current |
| Aruna Dharmeshappa | Whole-Time Director | 05-Jan-2015 | Current |
Financial Performance of Impilo Pharmaceuticals.
Impilo Pharmaceuticals Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 20.36% increase. The company also saw a substantial improvement in profitability, with a 198.18% increase in profit. The company's net worth Soared by an impressive increase of 36.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Impilo Pharmaceuticals?
In 2019, Impilo Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Impilo Pharmaceuticals?
Unlock and access historical data on people associated with Impilo Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Impilo Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Impilo Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
